Drug Profile
Apalutamide - Janssen Research and Development
Alternative Names: ARN-509; ERLEADA; Erleada; ERLYAND; JNJ-56021927; JNJ-927Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Aragon Pharmaceuticals; University of California
- Developer Aragon Pharmaceuticals; Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; M. D. Anderson Cancer Center; Singapore General Hospital
- Class Antiandrogens; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Phase II Salivary gland cancer
Most Recent Events
- 25 Jan 2024 Updated efficacy and adverse events data from a phase II trial in prostate cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GCS-2024)
- 25 Jan 2024 Updated efficacy data from the phase III TITAN trial in Prostate cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 13 Dec 2023 Aragon Pharmaceuticals completes a phase III expanded access protocol trial in Prostate cancer (Adjunctive treatment, Hormone refractory) in Brazil, Mexico and Colombia (PO) (NCT03523338)